- Home
- SPH vs ANAB Comparison
SPH vs ANAB Comparison
Compare SPH & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPH | ANAB |
|---|---|---|
| Founded | 1945 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 1996 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SPH | ANAB |
|---|---|---|
| Price | $19.34 | $45.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $60.18 |
| AVG Volume (30 Days) | 157.3K | ★ 532.7K |
| Earning Date | 02-05-2026 | 02-26-2026 |
| Dividend Yield | ★ 6.71% | N/A |
| EPS Growth | ★ 42.10 | N/A |
| EPS | ★ 1.62 | N/A |
| Revenue | ★ $1,432,518,000.00 | $169,467,000.00 |
| Revenue This Year | $2.06 | $135.51 |
| Revenue Next Year | $1.64 | N/A |
| P/E Ratio | $11.95 | ★ N/A |
| Revenue Growth | 7.94 | ★ 196.42 |
| 52 Week Low | $17.30 | $12.21 |
| 52 Week High | $22.24 | $52.47 |
Technical Indicators
Market Signals| Indicator | SPH | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 61.99 | 51.23 |
| Support Level | $18.90 | $42.50 |
| Resistance Level | $19.21 | $50.50 |
| Average True Range (ATR) | 0.36 | 3.19 |
| MACD | 0.10 | -0.33 |
| Stochastic Oscillator | 93.10 | 48.11 |
Price Performance
Historical ComparisonAbout SPH Suburban Propane Partners L.P.
Suburban Propane Partners LP distributes propane, fuel oil, and other refined fuels to customers in the East Coast and West Coast regions of the United States. Other operations include natural gas and electricity marketing in the deregulated New York and Pennsylvania markets. The company operates in three segments: Propane; Fuel Oil and Refined Fuels; and Natural Gas and Electricity. It generates maximum revenue from Propane segment.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).